Abstract:The purpose of the study was to compare the efficacy and safety of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy. This was an open-label, randomized, controlled, "real-life" trial. HBeAg-positive CHB patients with serum HBV DNA ≥5.0 lg IU/mL and a < 1 lg IU/mL decline of HBsAg level from baseline who underwent at least 24 weeks of Peg-IFNα-2a therapy were included. Enrolled patients were randomized to receive either telbivudine (600 mg/d, n = 95) or entecavir (0.5 mg/d, n = 95) for 208 consecutive weeks. Six patients were lost to follow-up (4 patients in the telbivudine group and 2 in the entecavir group). Treatment was combined with adefovir when week 24 HBV DNA levels declined to <2 lg IU/mL versus baseline, when viral breakthrough occurred during treatment,or when HBV DNA remained detectable at 52 weeks (HBV DNA ≥500 IU/mL). Responses and safety were assessed after 208 weeks of treatment. There were no significant differences among the baseline characteristics, including age, gender, and ALT, HBV DNA, HBsAg or HBeAg levels. After 208 weeks of treatment, there was no significant difference in the rates of undetectable HBV DNA (HBV DNA<500 IU/mL) between the telbivudine group and the entecavir group (84/91,92.31% vs 88/93,94.62%, respectively, P = .525). More patients in the telbivudine group than the entecavir group achieved HBeAg clearance (74.73% vs 46.24%, respectively, P < .001) and HBeAg seroconversion (64.84% vs 38.71%, respectively, P < .001). Univariate analysis (Enter, a = 0.05) of both groups showed that telbivudine, male gender and baseline HBeAg levels were significantly correlated with HBeAg seroconversion after 208 weeks of sequential therapy. Cox regression analysis (Enter, a = 0.05) of the telbivudine group showed that the HBeAg seroconversion rate at 208 weeks was significantly correlated with gender (male) (P = .006, HR=4.406), baseline HBeAg level (P = .005, HR=0.433) and 24 w-HBeAg level reduction of more than 0.5 lg IU/ml from baseline (P = .027, HR=0.487). All patients tolerated sequential telbivudine treatment; only slightly elevated creatine kinase levels were observed. Stratification analysis found that patients with baseline HBeAg levels less than 3 lg COI who switched to telbivudine may have had significantly improved HBeAg seroconversion rates. In conclusion, telbivudine promotes HBeAg seroconversion that merits investigation in HBeAg-positive CHB patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy. We would suggest that patients with baseline HBeAg levels under 3 lg COI switch to telbivudine to achieve higher HBeAg seroconversion rates and use the early reductions in HBeAg levels (24 weeks) to guide treatment.

Efficacy of Switching to Telbivudine in Chronic Hepatitis B Patients Treated Previously with Lamivudine

Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of A Randomized, Double-Blind Trial

Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients

Effect of Telbivudine Therapy on the Cellular Immune Response in Chronic Hepatitis B

Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.

P414 ASSESSMENT OF THE CHANGE IN ESTIMATED GLOMERULAR FILTRATION RATES IN TELBIVUDINE- OR LAMIVUDINE-BASED TRERAPY IN PATIENTS WITH CHRONIC HEPATITIS B

Meta Analysis of the Comparison of the Efficacy of Lamivudine and Telbivudine in the Treatment of Chronic Hepatitis B

Efficacy and Safety of 12 Weeks-Entecavir Treatment in HBeAg-negative Chronic Hepatitis B Patients with Acute-on-chronic Liver Failure in Comparison to Lamivudine

The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.

910 A PROSPECTIVE, RANDOMIZED STUDY OF EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A VERSUS ADEFOVIR DIPIVOXIL IN TREATING LAMIVUDINE- RESISTANT HBeAg-POSITIVE CHB

Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.

Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial

Randomized, Three-Arm Study To Optimize Lamivudine Efficacy In Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir

[Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients]

Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B.

Two-year Lamivudine Treatment for Hepatitis B E Antigen-Negative Chronic Hepatitis B: A Double-Blind, Placebo-Controlled Trial

A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China

Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine